{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:05:44Z","timestamp":1791918344402,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013412","name":"Sanofi Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40263-024-01066-3","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T15:02:42Z","timestamp":1709132562000},"page":"231-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study"],"prefix":"10.1007","volume":"38","author":[{"given":"Lucienne","family":"Costa-Frossard Fran\u00e7a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Meca Lallana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Labiano-Fontcuberta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Monreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Mart\u00ednez Gin\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sabin Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Sainz de la Maza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Cuello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"D\u00edaz-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Chico Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lozano Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rodr\u00edguez Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Mart\u00ednez Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Garc\u00eda Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"1066_CR1","doi-asserted-by":"crossref","unstructured":"Freedman MS, Kaplan JM, Markovic-Plese S. Insights into the mechanisms of the therapeutic efficacy of alemtuzumab in multiple sclerosis. J Clin Cell Immunol. 2013;4(4):1000152.","DOI":"10.4172\/2155-9899.1000152"},{"key":"1066_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet. 2012. https:\/\/doi.org\/10.1016\/S0140-6736(12)61769-3.","journal-title":"The Lancet"},{"key":"1066_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802670","author":"CT Investigators","year":"2008","unstructured":"Investigators CT, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008. https:\/\/doi.org\/10.1056\/NEJMoa0802670.","journal-title":"N Engl J Med"},{"key":"1066_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet. 2012. https:\/\/doi.org\/10.1016\/S0140-6736(12)61768-1.","journal-title":"The Lancet"},{"key":"1066_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004354","author":"AJ Coles","year":"2017","unstructured":"Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017. https:\/\/doi.org\/10.1212\/WNL.0000000000004354.","journal-title":"Neurology"},{"key":"1066_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004313","author":"E Havrdova","year":"2017","unstructured":"Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology. 2017. https:\/\/doi.org\/10.1212\/WNL.0000000000004313.","journal-title":"Neurology"},{"key":"1066_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09983-1","author":"B Steingo","year":"2020","unstructured":"Steingo B, Al Malik Y, Bass AD, Berkovich R, Carraro M, Fern\u00e1ndez \u00d3, et al. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020. https:\/\/doi.org\/10.1007\/s00415-020-09983-1.","journal-title":"J Neurol"},{"key":"1066_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00749-x","author":"T Ziemssen","year":"2020","unstructured":"Ziemssen T, Bass AD, Berkovich R, Comi G, Eichau S, Hobart J, et al. Efficacy and safety of alemtuzumab through 9 years of follow-up in patients with highly active disease: post hoc analysis of CARE-MS I and II patients in the TOPAZ extension study. CNS Drugs. 2020. https:\/\/doi.org\/10.1007\/s40263-020-00749-x.","journal-title":"CNS Drugs"},{"key":"1066_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101504","author":"M di Ioia","year":"2020","unstructured":"di Ioia M, Di Stefano V, Farina D, Di Tommaso V, Travaglini D, Pietrolongo E, et al. Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: a report from a single Italian center. Mult Scler Relat Disord. 2020. https:\/\/doi.org\/10.1016\/j.msard.2019.101504.","journal-title":"Mult Scler Relat Disord."},{"key":"1066_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1112193","author":"S Eichau","year":"2023","unstructured":"Eichau S, Lopez Ruiz R, Ruiz de Arcos M, Ruiz-Pena JL, Navarro G, Calleja MA, et al. Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study. Front Neurol. 2023. https:\/\/doi.org\/10.3389\/fneur.2023.1112193.","journal-title":"Front Neurol"},{"key":"1066_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09272-6","author":"J Frau","year":"2019","unstructured":"Frau J, Coghe G, Lorefice L, Fenu G, Musu L, Cocco E. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis. J Neurol. 2019. https:\/\/doi.org\/10.1007\/s00415-019-09272-6.","journal-title":"J Neurol"},{"key":"1066_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9070-x","author":"L Prosperini","year":"2018","unstructured":"Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, et al. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. J Neurol. 2018. https:\/\/doi.org\/10.1007\/s00415-018-9070-x.","journal-title":"J Neurol"},{"key":"1066_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15121","author":"CV Russo","year":"2022","unstructured":"Russo CV, Sacca F, Frau J, Annovazzi P, Signoriello E, Bonavita S, et al. A real-world study of alemtuzumab in a cohort of Italian patients. Eur J Neurol. 2022. https:\/\/doi.org\/10.1111\/ene.15121.","journal-title":"Eur J Neurol"},{"key":"1066_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1265354","author":"S Sandgren","year":"2023","unstructured":"Sandgren S, Novakova L, Nordin A, Axelsson M, Malmestrom C, Zetterberg H, et al. A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis. Front Neurol. 2023. https:\/\/doi.org\/10.3389\/fneur.2023.1265354.","journal-title":"Front Neurol"},{"key":"1066_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211003291","author":"A Theodorsdottir","year":"2021","unstructured":"Theodorsdottir A, Debrabant B, Magyari M, Kant M, Rasmussen PV, Malmberg CF, et al. Alemtuzumab treatment in Denmark: a national study based on the Danish Multiple Sclerosis Registry. Mult Scler. 2021. https:\/\/doi.org\/10.1177\/13524585211003291.","journal-title":"Mult Scler"},{"key":"1066_CR16","unstructured":"Ziemssen T, Hoffmann F, Richter S, Engelmann U, Quint L, Group T-MS. Real-world effectiveness of alemtuzumab in RRMS patients in Germany: Interim results of the TREAT-MS study after completion of recruitment. In: 2021; 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2021. p. October 13-5, 2021."},{"key":"1066_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617722706","author":"T Ziemssen","year":"2017","unstructured":"Ziemssen T, Thomas K. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord. 2017. https:\/\/doi.org\/10.1177\/1756285617722706.","journal-title":"Ther Adv Neurol Disord"},{"key":"1066_CR18","unstructured":"Last updated 2019 [cited; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lemtrada-epar-product-information_en.pdf."},{"key":"1066_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22366","author":"CH Polman","year":"2010","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2010. https:\/\/doi.org\/10.1002\/ana.22366.","journal-title":"Ann Neurol"},{"key":"1066_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.620758","author":"T Ziemssen","year":"2021","unstructured":"Ziemssen T, Hoffmann F, Richter S, Engelmann U, White R. Alemtuzumab in a large real-life cohort: interim baseline data of the TREAT-MS study. Front Neurol. 2021. https:\/\/doi.org\/10.3389\/fneur.2021.620758.","journal-title":"Front Neurol"},{"key":"1066_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102945","author":"G Bose","year":"2021","unstructured":"Bose G, Rush C, Atkins HL, Freedman MS. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. Mult Scler Related Disord. 2021. https:\/\/doi.org\/10.1016\/j.msard.2021.102945.","journal-title":"Mult Scler Related Disord"},{"key":"1066_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05145-x","author":"G Brecl Jakob","year":"2021","unstructured":"Brecl Jakob G, Barun B, Gomezelj S, Gabelic T, Sega Jazbec S, Adamec I, et al. Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study. Neurol Sci. 2021. https:\/\/doi.org\/10.1007\/s10072-021-05145-x.","journal-title":"Neurol Sci"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01066-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01066-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01066-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T15:09:59Z","timestamp":1710083399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01066-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01066-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"1 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study, manuscript preparation, and open access was funded by Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"EM declares receipt of consulting and advisory board fees from Sanofi. He reports receiving research grants, travel support, or honoraria for speaking engagements from Biogen, Sanofi, Merck, Novartis, Almirall, Roche, BMS, and Janssen outside the submitted work. CA declares receipt of grants, travel support, or honoraria for speaking engagements from Biogen, Janssen, Merck, Novartis, Roche, and Sanofi. JSM declares receipt of travel and educational support or honoraria for speaking engagements from Almirall, Biogen, Janssen, Merck, Novartis, Roche, Sanofi, and Teva. SSdM declares receipt of travel support, honoraria for speaking, and consulting fees from Sanofi. JPC declares receipt of consulting fees, support for travel, fees honoraria for participation on data monitoring boards, speaking honoraria, and expert testimony from Novartis, Biogen, Merck, Sanofi, and Roche. JLCG has received honoraria for speaking engagements or consulting services from Biogen, Bayer, Bial, and Sanofi. SMM is an employee of Sanofi. JMGD has received fees as speaker or advisor and travel or research grants from Almirall, Biogen, Roche, Sanofi, Janssen, BMS, Merck, and Novartis. LCFF, VML, ALF, RB, MLMG, CDP, ALR, and FRJ declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and national regulations. Approval was granted by the Ethics Committee of Hospital Ram\u00f3n y Cajal (Madrid, Spain).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent for the collection of data from their medical records.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data supporting the results reported in the article will be made available from the corresponding author upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"LCFF, VML, SMM, and JMGD made substantial contributions to the conception and design of the work, interpretation of data, and drafting the manuscript. All authors contributed to the acquisition of data and revised the manuscript critically for important intellectual content. All authors approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}